Technical420 Site Search

Last week, we started to highlight some of the best performing cannabis stocks and initially covered Innovative Industrial Properties, Inc. (NYSE: IIPR), a cannabis real estate investment trust (REIT).  When you combine price appreciation and dividend income from Innovative Industrial Properties, the stock has returned more than 1,500% since the…

Last week, marked another milestone of the legal cannabis industry after Jazz Pharmaceuticals (Nasdaq: JAZZ) completed the acquisition of GW Pharmaceuticals plc., a leader in the science, development and commercialization of cannabinoid-based prescription medicines. Although the acquisition did receive as much attention as the merger between Aphria and Tilray, Inc. (TLRY.TO)…

GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced financial results and operating progress for the fourth quarter and full-year ended December 31, 2020. “We are very proud of our strong financial performance and operational progress in 2020, as…

From a merger and acquisition (M&A) standpoint, the cannabis sector recently seen a spike in activity, and this is a trend that we expect to become more significant over the next few years. Last week, GW Pharmaceuticals plc (GWPH) reported to have entered into a definitive agreement with Jazz Pharmaceuticals…

Earlier this week, the cannabis industry saw it largest acquisition in the history of the sector and this is a headline that caught the attention of major financial media firms. GW Pharmaceuticals plc (GWPH) was the target of the acquisition and it reported to have entered into a definitive agreement…

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and GW Pharmaceuticals plc (Nasdaq: GWPH) today announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration…

GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full year 2020 and key priorities for 2021. Justin Gover, GW’s Chief Executive Officer, expects to discuss these updates as…

This morning, Nasdaq-traded biotech firm GW Pharmaceuticals (GWPH) reported its fourth quarter earnings and the shares are trending higher in pre-market trading.The company also announced additional positive Epidiolex Phase 3 data in poster presentations at the 70th Annual Meeting of the American Epilepsy Society. The studies represented in the posters…

The cannabis industry continues to be one of the greatest beneficiaries of the upcoming election as several states are set to vote on legal cannabis initiatives.The cannabis industry is currently experiencing unprecedented growth and the industry is barely in the first inning of what we expect to be a multi-decade…

GW Pharmaceuticals plc (GWPH) is a pharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform. GWPH commercialized the world's first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United…